Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and SBRT in Stage IIIB/C-IV NSCLC
NCT07198217Phase 2Recruiting
- Sponsor
- Zibo Municipal Hospital
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Zibo Municipal Hospital. Started May 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07198217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198217.